| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Bringing an end to diabetes stigma and discrimination: an international consensus statement on evidence and recommendations
|
Speight, Jane
|
|
|
12 |
1 |
p. 61-82
|
article
|
| 2 |
Correction to Lancet Diabetes Endocrinol 2023; 11: 905–14
|
|
|
|
12 |
1 |
p. e1
|
article
|
| 3 |
Correction to Lancet Diabetes Endocrinol 2023; 11: 798–810
|
|
|
|
12 |
1 |
p. e1
|
article
|
| 4 |
Correction to Lancet Diabetes Endocrinol 2023; 11: 942–54
|
|
|
|
12 |
1 |
p. e1
|
article
|
| 5 |
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
|
|
|
|
12 |
1 |
p. 39-50
|
article
|
| 6 |
Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial
|
Ray, Kausik K
|
|
|
12 |
1 |
p. 19-28
|
article
|
| 7 |
Empagliflozin in chronic kidney disease: nephroprotection is independent of albuminuria, primary kidney disease, and baseline eGFR
|
Zoccali, Carmine
|
|
|
12 |
1 |
p. 5-8
|
article
|
| 8 |
Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses
|
|
|
|
12 |
1 |
p. e2-e11
|
article
|
| 9 |
From research to policy: still a long way to go
|
The Lancet Diabetes & Endocrinology,
|
|
|
12 |
1 |
p. 1
|
article
|
| 10 |
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
|
|
|
|
12 |
1 |
p. 51-60
|
article
|
| 11 |
Is a new discussion about diagnosis of gestational diabetes needed?
|
Desoye, Gernot
|
|
|
12 |
1 |
p. 11-12
|
article
|
| 12 |
Mendelian randomisation at 20 years: how can it avoid hubris, while achieving more?
|
Smith, George Davey
|
|
|
12 |
1 |
p. 14-17
|
article
|
| 13 |
New clarity for managing statin intolerance in diabetes
|
Hegele, Robert A
|
|
|
12 |
1 |
p. 2-3
|
article
|
| 14 |
Retraction and republication—Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses
|
The Editors of The Lancet Diabetes & Endocrinology,
|
|
|
12 |
1 |
p. 8
|
article
|
| 15 |
Screening type 1 diabetes and celiac disease by law
|
Bosi, Emanuele
|
|
|
12 |
1 |
p. 12-14
|
article
|
| 16 |
South Africa to produce insulin for Africa in 2024
|
Makoni, Munyaradzi
|
|
|
12 |
1 |
p. 18
|
article
|
| 17 |
The Lancet Diabetes & Endocrinology Commission on type 1 diabetes: looking back to move forward
|
Beran, David
|
|
|
12 |
1 |
p. 9-11
|
article
|
| 18 |
The role of vitamin D in paediatric bone health
|
Pettifor, John M
|
|
|
12 |
1 |
p. 4-5
|
article
|
| 19 |
Vitamin D supplements for fracture prevention in schoolchildren in Mongolia: analysis of secondary outcomes from a multicentre, double-blind, randomised, placebo-controlled trial
|
Ganmaa, Davaasambuu
|
|
|
12 |
1 |
p. 29-38
|
article
|
Journal description